💰 Italian biotech Resalis Therapeutics has raised €10m ($11.2m) in a Series A financing round led by Sunstone Life Science Ventures. The funding will be used to complete a Phase I study for the company’s obesity treatment, RES-010. The therapy is a non-coding locked anti miRNA22 antisende-RNA that aims to provide a longer-lasting weight-reduction effect in combination with existing obesity drugs.
📢 Biotech Start-up Raises €10m for Revolutionary Obesity Treatment
E://resalis-therapeutics-srl. raises-€10m-in-series-a-financing
Italian company Resalis Therapeutics Srl has secured €10m in a Series A financing round led by Sunstone Life Science Ventures. The funding will be used to complete a Phase I study for RES-010, Resalis’ lead program in treating obesity. RES-010 is a non-coding locked anti miRNA22 antisende-RNA designed to provide a disease-modifying approach in obesity with longer-lasting weight reduction. The company plans to initiate a Phase I clinical study in the first half of 2024.
